CN102725284A - 适用于治疗共核蛋白病的化合物 - Google Patents

适用于治疗共核蛋白病的化合物 Download PDF

Info

Publication number
CN102725284A
CN102725284A CN2010800568024A CN201080056802A CN102725284A CN 102725284 A CN102725284 A CN 102725284A CN 2010800568024 A CN2010800568024 A CN 2010800568024A CN 201080056802 A CN201080056802 A CN 201080056802A CN 102725284 A CN102725284 A CN 102725284A
Authority
CN
China
Prior art keywords
compound
group
disease
compounds
syn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800568024A
Other languages
English (en)
Chinese (zh)
Inventor
E·玛斯莉亚
E·M·罗肯施泰因
W·瓦斯德洛
I·F·齐格尔尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuropore Therapies Inc
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of CN102725284A publication Critical patent/CN102725284A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800568024A 2009-12-16 2010-12-16 适用于治疗共核蛋白病的化合物 Pending CN102725284A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28708209P 2009-12-16 2009-12-16
US61/287,082 2009-12-16
PCT/US2010/060862 WO2011084642A1 (en) 2009-12-16 2010-12-16 Compound suitable for the treatment of synucleopathies

Publications (1)

Publication Number Publication Date
CN102725284A true CN102725284A (zh) 2012-10-10

Family

ID=43629477

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800568024A Pending CN102725284A (zh) 2009-12-16 2010-12-16 适用于治疗共核蛋白病的化合物

Country Status (12)

Country Link
US (2) US8846682B2 (2)
EP (1) EP2513090A1 (2)
JP (2) JP5922031B2 (2)
KR (1) KR20120112548A (2)
CN (1) CN102725284A (2)
AU (1) AU2010339841B2 (2)
BR (1) BR112012014807A2 (2)
CA (1) CA2784744A1 (2)
MX (1) MX335989B (2)
NZ (1) NZ600449A (2)
RU (1) RU2012129882A (2)
WO (1) WO2011084642A1 (2)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104530013A (zh) * 2014-12-04 2015-04-22 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
CN106132960A (zh) * 2014-01-29 2016-11-16 神经孔疗法股份有限公司 用作蛋白质聚集抑制剂的杂芳基酰胺
CN110191885A (zh) * 2017-01-26 2019-08-30 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物
CN110198938A (zh) * 2017-01-26 2019-09-03 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的双-杂芳基衍生物
WO2023125376A1 (zh) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014011615A (es) * 2012-03-28 2015-01-19 Neuropore Therapies Inc Derivados de fenil-urea y fenil-carbamato como inhibidores de agregacion de proteina.
CN104703604A (zh) 2012-07-16 2015-06-10 神经孔疗法股份有限公司 作为蛋白质聚集抑制剂的二-和三-杂芳基衍生物
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
EP3328379B1 (en) * 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
EA201991755A1 (ru) 2017-01-26 2020-01-22 Юсб Байофарма Спрл Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
US12178805B2 (en) 2017-05-11 2024-12-31 Remynd N.V. Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
WO2018206760A1 (en) 2017-05-11 2018-11-15 Remynd N.V. Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders
TW202415651A (zh) 2022-07-29 2024-04-16 日商住友製藥股份有限公司 含氮飽和雜環衍生物
TW202412787A (zh) 2022-07-29 2024-04-01 日商住友製藥股份有限公司 2(1h)-吡啶亞胺衍生物
WO2024102758A2 (en) * 2022-11-08 2024-05-16 The General Hospital Corporation N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054410A1 (en) * 2006-02-07 2009-02-26 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726263A3 (en) * 1995-02-08 1996-10-09 American Cyanamid Co Herbicides (1,3,4) oxadiazoles and thiadiazoles
US5591695A (en) * 1995-02-08 1997-01-07 American Cyanamid Co. Herbicidal [1,3,4]oxadiazoles and thiadiazoles
EP0946587A2 (en) * 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
US6096688A (en) * 1996-12-27 2000-08-01 American Cyanamid Company Oxazole carboxamide herbicides
JP2007519753A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
CA2580767A1 (en) * 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
KR101394245B1 (ko) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
WO2009129532A1 (en) * 2008-04-18 2009-10-22 University Of Connecticut Compounds for lysosomal modulation and methods of use
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054410A1 (en) * 2006-02-07 2009-02-26 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132960A (zh) * 2014-01-29 2016-11-16 神经孔疗法股份有限公司 用作蛋白质聚集抑制剂的杂芳基酰胺
CN106132960B (zh) * 2014-01-29 2019-12-17 优时比生物医药有限公司 用作蛋白质聚集抑制剂的杂芳基酰胺
CN111039939A (zh) * 2014-01-29 2020-04-21 优时比生物医药有限公司 用作蛋白质聚集抑制剂的杂芳基酰胺
CN111039939B (zh) * 2014-01-29 2023-09-19 优时比生物医药有限公司 用作蛋白质聚集抑制剂的杂芳基酰胺
CN104530013A (zh) * 2014-12-04 2015-04-22 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
CN104530013B (zh) * 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
CN110191885A (zh) * 2017-01-26 2019-08-30 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物
CN110198938A (zh) * 2017-01-26 2019-09-03 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的双-杂芳基衍生物
CN110198938B (zh) * 2017-01-26 2023-03-14 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的双-杂芳基衍生物
CN110191885B (zh) * 2017-01-26 2023-05-16 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物
WO2023125376A1 (zh) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Also Published As

Publication number Publication date
US20130035342A1 (en) 2013-02-07
US20140364610A1 (en) 2014-12-11
WO2011084642A1 (en) 2011-07-14
AU2010339841A1 (en) 2012-07-05
CA2784744A1 (en) 2011-07-14
JP2013514980A (ja) 2013-05-02
RU2012129882A (ru) 2014-01-27
BR112012014807A2 (pt) 2017-06-27
NZ600449A (en) 2014-10-31
MX335989B (es) 2016-01-07
US8846682B2 (en) 2014-09-30
MX2012006740A (es) 2012-09-07
EP2513090A1 (en) 2012-10-24
KR20120112548A (ko) 2012-10-11
JP5922031B2 (ja) 2016-05-24
AU2010339841B2 (en) 2014-09-25
JP2016074679A (ja) 2016-05-12

Similar Documents

Publication Publication Date Title
CN102725284A (zh) 适用于治疗共核蛋白病的化合物
RU2429237C2 (ru) N-(2-тиазолил)амидные производные в качестве ингибиторов gsk-3
US8980899B2 (en) Methods of inhibiting Ire1
US8252829B2 (en) Aminopyrrolidinone derivatives and uses thereof
JP6518270B2 (ja) Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン
BR112021000395A2 (pt) Compostos imunomoduladores diméricos contra mecanismos baseados em cereblon
CN110914253B (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
WO2011156632A2 (en) Compositions and methods of treatment for tumors in the nervous system
JP2014129406A (ja) ＴＮＦαシグナル伝達のモジュレータ
WO2011029832A1 (de) Neue thiazol- und oxazol-hepcidin-antagonisten
TR201906325T4 (tr) Tetrazolon sübstitüeli dihidropiridinon MGAT2 inhibitörleri.
US20190161476A1 (en) Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine
EP4052706A1 (en) Composition for preventing or inhibiting axonal degeneration
KR20070086188A (ko) 키나제 억제제
TW202334148A (zh) 用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法
CA2841897A1 (en) Novel compound having parp inhibitory activity
BR112019012709A2 (pt) composto, método para tratar e/ou prevenir uma doença distinguida por sinalização deficiente de neurotrofinas e/ou outros fatores tróficos, uso de um composto, composição farmacêutica, produto de combinação, kit de peças, e, processos para preparação de um composto e de uma composição farmacêutica.
US20230109505A1 (en) Small molecule inhibitors of scl15a4 with anti-inflammatory activity
CN117083065A (zh) 肌肉减少症相关疾病等的新颖治疗和预防
CN107428730B (zh) 作为抗癌试剂的1,3,5-三嗪基pi3k抑制剂及其制备方法
AU2014271313A1 (en) Compound suitable for the treatment of synucleopathies
WO2005054229A1 (fr) Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
WO2024146631A1 (zh) 一种parp7抑制剂的制备方法
CN106660971A (zh) 用于神经退行性疾病和阿尔茨海默病的治疗中的用途的双重抑制剂化合物
SA et al. SYNTHESIS, MOLECULAR DOCKING & EVALUATION OF ANTHELMINTIC ACTIVITY OF 2-(2-AMINO PHENYL)-1H-BENZIMIDAZOLE DERIVATIVES

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121010